Published online before print May 15, 2003, doi: 10.1161/01.ATV.0000077401.36885.BB
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2003 American Heart Association, Inc.
Atherosclerosis and Lipoproteins |
Plasma PAI-1 Levels Are More Strongly Related to Liver Steatosis Than to Adipose Tissue Accumulation
From the Laboratory of Hematology (M.-C.A., D.B., A.M., P.M., I.J.-V.), EPI 99[hyphen]36, Faculty of Medicine, Marseille, France; the Department of Angiology (A.M.), University Medical Centre, Ljubljana, Slovenia; the Department of Gastric Surgery (B.B.), CHU Timone, Marseille, France; the Service d’Endocrinologie (M.G.), Maladies Métaboliques et Nutrition, CHU Nord, Marseille, France; and the Centre d’Investigation Clinique (M.-C.A., P.M., I.J.-V.), AP-HM INSERM 95-02, Hôpital Ste. Marguerite, Marseille, France.
Correspondence to Pr M.C. Alessi, Laboratoire d’Hématologie, EPI 9936, 27, Bd Jean Moulin, 13385 Marseille Cedex 5, France. E-mail Marie-Christine.Alessi{at}medecine.univ-mrs.fr
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Objective— Because obesity and insulin resistance (IR) are strongly associated with liver steatosis (LS), we investigated the relation between the degree of LS and plasminogen activator inhibitor-1 (PAI-1) in ob/ob mice, in C57/BL6 mice with alcoholic LS, and in severely obese humans.
Methods and Results— In both mouse models, plasma PAI-1 levels were associated with PAI-1 expression in the liver and with the degree of LS. Liver PAI-1 antigen was associated with the tumor necrosis factor receptor-II (TNFRII) antigen, whereas association with TNF antigen content was found in ob/ob mice only. No significant correlation between plasma PAI-1 and PAI-1 expression in adipose tissue of ob/ob mice was observed. Furthermore, the relation between plasma PAI-1 levels and body weight was positive in ob/ob mice but negative in C57/BL6 mice (both P<0.001). In humans, PAI-1 levels were correlated with the degree of LS, and 26% of plasma PAI-1 activity was independently explained by LS and serum insulin levels.
Conclusions— Plasma PAI-1 levels are more closely related to fat accumulation and PAI-1 expression in the liver than in adipose tissue. In steatotic liver, PAI-1 antigen content is associated with those of TNF and TNFRII. Therefore, we suggest that TNF pathway dysregulation in LS could be involved in increased plasma PAI-1 in obesity with IR.
Key Words: liver steatosis • PAI-1 • adipose tissue • insulin resistance
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Plasminogen activator inhibitor type 1 (PAI-1) is the main inhibitor of fibrinolysis. PAI-1 modulates the development of atherosclerosis in mice,1,2 and an elevated plasma PAI-1 concentration is predictive for myocardial infarction in humans.3,4 Interestingly, the predictive value of circulating PAI-1 levels is highly dependent on the insulin resistance syndrome.4,5
Despite several efforts in the last few years, the mechanism of increased plasma PAI-1 concentration in insulin resistance associated with android obesity is not completely understood. PAI-1 is expressed in murine as well as in human adipose tissue,6–9 and its expression in adipose tissue is correlated positively with body mass index (BMI).9–11 Human visceral adipose tissue expresses more PAI-1 than does subcutaneous abdominal adipose tissue.7,12 Furthermore, PAI-1 expression in only abdominal, but not in femoral subcutaneous adipose tissue, is associated with the features of insulin resistance.11 Therefore, it has been postulated that in the insulin resistance syndrome with central obesity, abdominal adipose tissue is an important source of plasma PAI-1. Of note, an increase in plasma PAI-1 is also observed in lipodystrophy associated with antiretroviral treatment in HIV patients. These patients typically have prominent, peripheral fat wasting and maintained or decreased visceral fat depots and are insulin resistant. Interestingly, the difference in plasma PAI-1 levels between HIV patients and healthy controls was independent of HIV infection status and was not affected after adjustment for visceral fat estimation but was rather explained by metabolic disturbances such as hyperinsulinemia.13 Recently, a close relation between plasma PAI-1 levels and the amount of liver fat was described in these patients.14
Indeed, besides insulin resistance, nonalcoholic liver steatohepatitis (NASH) is a common feature of android obesity and lipodystropy.15,16 Patients with NASH have increased serum levels of 
-glutamyltransferase (-GT), alanine aminotransferase (ALT), and aspartate aminotransferase (AST).17 Hepatic enzyme activity is associated with plasma PAI-1 levels in hyperlipemic as well as in normolipemic subjects.18–22 Furthermore, in ob/ob mice, which usually develop fatty liver, and in rabbits fed a high-fat diet, an increased PAI-1 expression was observed in liver.8,23 PAI-1 is produced by cultured, human hepatoma HepG2 cells and by freshly isolated human hepatocytes and is increased under insulin stimulation.24–26 These data suggest that the liver could be involved in plasma PAI-1 regulation. However, data on the relation between plasma PAI-1 levels and NASH are scanty.
In this study, the relation between PAI-1 and liver steatosis was evaluated in the murine model of genetically obese, insulin-resistant ob/ob mice with NASH and in the murine model of alcohol-induced liver steatosis. Also, the relation between PAI-1 and NASH was studied in a population of morbidly obese humans.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Murine Models
Genetically Obese, Insulin-Resistant ob/ob Mice
Eight-week-old male ob/ob mice (n=10; Elevage, Janvier, France) were fed a high-fat, liquid diet (47% carbohydrate, 35% fat, 18% protein; Lieber-DeCarli Control, BioServ) ad libitum for 5 weeks. Mice were euthanized by cervical dislocation after an overnight fast, always at the same time of day. Blood was collected by retro-orbital puncture into tubes with anticoagulant (0.01 mol/L trisodium citrate) and centrifuged for 15 minutes at 3000g to obtain plasma. Liver, intra-abdominal (epididymal), and subcutaneous (inguinal) entire adipose tissue territories were removed, weighed, and immediately frozen in LN2.
Alcohol-Induced Liver Steatosis in C57/BL6 Mice
Eight-week-old female C57/BL6 mice (n=15; Elevage, Depré, France) were fed an ethanol-high-fat liquid diet, which provided 1 kcal/mL and contained 36% ethanol, 35% fat, 18% protein, and 11% carbohydrate (Lieber-DeCarli Regular Ethanol Dyets Inc). Control C57/BL6 mice (n=15) were pair-fed a control diet in which ethanol was replaced isocalorically with maltose dextrin (Lieber-DeCarli Regular Control Dyets Inc). Euthanasia and blood sampling were performed as described for ob/ob mice. The liver only was collected, because the amount of adipose tissue territories was negligible. All experiments in animals were performed in accordance with the guiding principles of the ethics committee of the Faculty of Medicine, Marseille, France.
Morbidly Obese Humans
Forty morbidly obese subjects (BMI>35 kg/m2), 33 women and 7 men, with a mean age of 40 years (range, 23 to 59 years), were recruited at the Gastric Surgery Department, University Hospital Timone, Marseille, France. They had been admitted to the department for treatment of their obesity by gastroplasty. In the control group, there were 28 lean, apparently healthy volunteers, 21 women and 7 men, with a mean age of 40 years (range, 24 to 56 years). Ten obese subjects had type 2 diabetes, and 8 were being treated with hypoglycemic drugs, none with insulin. Four obese subjects were receiving antihypertensive drugs. None of the subjects had a history of a liver disease, alcohol abuse, or thromboembolic disease or suffered from any ongoing disease (eg, infection, cancer). In all obese subjects, gastroplasty was performed and liver biopsy specimens were taken as a routine part of the operative procedure. Tissue samples were immediately embedded in paraffin. Blood samples were taken between 7:30 and 9 AM. Platelet-poor plasma was obtained after centrifugation for 30 minutes at 2000 g and 4°C and stored at -70°C until analyzed. Informed, written consent was obtained from all subjects, and the study was conducted in conformance with the Helsinki Declaration.
Methods
Studies in Mice
Immunological Determination
PAI-1 antigen was determined by a home-made ELISA,27 and tumor necrosis factor-
(TNF) and TNF receptors I and II (TNFRI and TNFRII, respectively) were determined by specific ELISAs (R&D Systems). Values were expressed per milliliter of plasma or per total organ. In mice with alcohol-induced liver steatosis, adjustment per body weight was performed because of differences in body weight between the intervention and control groups.
Proteins, RNA, DNA, and Lipid Extractions
Tissue proteins were extracted as previously described.28 Total RNA from 200 to 250 mg adipose tissue or 30 to 40 mg liver was extracted by using a commercially available kit (RNeasy Mini Kit, Qiagen). The integrity of the RNA was confirmed by electrophoresis in ethidium bromide-containing agarose gels, and the RNA concentration was determined spectrophotometrically. DNA was extracted as proposed by Maniatis et al,29 except that two chloroform extractions were performed instead of one. The DNA concentration was determined spectrophotometrically. The method of Folch et al30 was used for lipid extraction.
Reverse Transcription and Relative Real-Time Polymerase Chain Reaction
Reverse transcription (RT) was performed on 2 µg total RNA, as previously described.10 Then the samples were diluted twice (for PAI-1 determination) or 1/1000 (for 18S) in sterile water. Amplification was performed in 25 µL on a thermal cycler (AbiPrism 7700, Perkin-Elmer). The polymerase chain reaction (PCR) conditions were as follows: 2 minutes at 50°C; 10 minutes at 95°C, followed by 40 cycles of a two-step PCR denaturation at 95°C for 15 seconds and annealing extension at 60°C for 60 seconds. Each sample contained 5 µL cDNA in 1x fluorescence fluid (SYBRGreen PCR Master Mix, Applied Biosystems) and 1 µL of each primer (400 nmol/L, Invitrogen). A control without cDNA was performed for each experiment. Primer express software (Applied Biosystems) was used to design primers for PAI-1 mRNA and 18S rRNA (housekeeping gene). For PAI-1 mRNA quantification, primers were 5'-ACA GCC TTT GTC ATC TCA GCC-3' (forward) and 5'-CCG AAC CAC AAA GAG AAA GGA-3' (reverse) (GenBank accession No. M33960). The primers for 18S rRNA were 5'-CTA CCA CAT CCA AGG AAG GCA-3' (forward) and 5'-TTT TTC GTC ACT ACC TCC CCG-3' (reverse) (GenBank accession No. X00686). With the use of this technology, several PCR cycles are required before the specific fluorescence signal emerges above background fluorescence. The number of cycles (CT) required to generate a threshold of 0.04 fluorescence units was determined in triplicate for each sample. The results of PAI-1 were normalized to those of 18S rRNA and expressed as a percentage of the sample chosen in each tissue; that was considered as 100% (user bulletin No. 2, Applied Biosystems).
Estimation of Liver Steatosis
Liver steatosis was estimated by determination of hepatic triglyceride content.
Study in Morbidly Obese Humans
Immunological and Biochemical Analyses
Plasma PAI-1 antigen and PAI-1 activity were assayed with commercially available kits (Asserachrom PAI-1, Diagnostica Stago, and Chromolize, Biopool International, respectively). HDL cholesterol, triglycerides, -GT, AST, and ALT concentrations were determined by routine biochemical methods. Insulin was assayed with an ELISA (Insulin Kit, Dako).
Estimation of Liver Steatosis
Human liver sections (5 µm) were mounted on slides (Superfrost Plus, CML), deparaffinized (MicroClear), and counterstained with Harris hematoxylin. Total and steatosis surfaces were automatically calculated by using a computerized image analyser (Samba 2005 TITN-Alcatel). Steatosis surface was defined as the surface of empty holes within the tissue. The mean surface analyzed per subject was 1.89 mm2 (range, 0.61 to 5.19 mm2). Results were expressed as a percentage of the total surface.
Statistical Analysis
In mice, data were expressed as mean ± SEM, and in humans, as the median and range between the 25th and 75th percentiles. Spearman’s correlation coefficient was used to examine relations among the variables. Differences in variables within the group of ob/ob mice were tested with the Wilcoxon test. Differences between C57/BL6 mice with and without alcoholic liver steatosis and differences between obese and lean subjects were tested by the Mann-Whitney U test. Stepwise multiple linear regression analysis was performed to evaluate the independence of associations. The independent variable was logarithmically transformed before being entered into the model. Significance was defined as P<0.05. Statistical analysis was performed with a software package (Statistica).
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Genetically Obese, Insulin-Resistant ob/ob Mice
Variables measured in ob/ob mice are shown in Table 1. PAI-1 antigen content in the liver was significantly higher than in subcutaneous or intra-abdominal fat (both P<0.05). Corresponding values for PAI-1 antigen expressed per gram of tissue were (mean±SEM) as follows: 317.3±43.7, 162.9±11.5, and 181.1±7.9 ng/g, respectively. PAI-1 mRNA was detected in the liver as well as in subcutaneous and intra-abdominal fat (mean±SEM, 109.2±27.6, 295.5±42.2, and 236.6±52.7 PAI-1 mRNA/18S rRNA as a percentage of control values, respectively). However, the method used for this determination (relative RT-PCR) does not allow comparison between these tissues, because the liver contained 25-fold more DNA per gram than did adipose tissue (data not shown).
|
A significant correlation was found between plasma PAI-1 levels and triglyceride content in the liver (r=0.82, P<0.004), PAI-1 antigen (r=0.65, P<0.05), and PAI-1 mRNA (r=0.70, P=0.02), and a positive association was also observed between plasma PAI-1 and body weight (Figure 1). Interestingly, liver PAI-1 mRNA expression was associated significantly and positively with liver steatosis (r=0.82, P<0.004), indicating that the degree of liver steatosis might influence PAI-1 expression in the liver.
|
In contrast to the relation obtained with variables measured in liver, there was no significant association between plasma PAI-1 levels and adipose tissue content of triglycerides, PAI-1 antigen (Figure 2), or PAI-1 mRNA. These results show that PAI-1 production in steatotic liver is more importantly connected with plasma PAI-1 level than PAI-1 production in adipose tissue.
|
Because it has been shown that TNF might be implicated in PAI-1 regulation in obesity,31 we quantified TNF and TNFRs antigens in the liver. We found a significant association between liver TNF or TNFRII and PAI-1 antigen content (r=0.80, P<0.01, and r=0.79, P<0.01, respectively). TNF antigen was associated with liver steatosis, with a borderline significance (r=0.61, P=0.06).
Alcohol-Induced Liver Steatosis in C57/BL6 Mice
Development of liver steatosis in mice on the alcohol diet was verified by histological analysis (data not shown). Variables measured in C57/BL6 mice with and without alcohol-induced liver steatosis are shown in Table 2; an adjustment for body weight was performed, because the two groups differed in body weight. Plasma PAI-1 levels, liver content of PAI-1 antigen, PAI-1 mRNA, TNFRII antigen, triglycerides, and liver mass were significantly higher in mice with alcoholic liver steatosis than in control mice.
|
A significant correlation was found between plasma PAI-1 levels and liver content of triglycerides (r=0.37, P=0.05), PAI-1 antigen (r=0.37, P=0.05), and PAI-1 mRNA (r=0.78, P=0.0002; Figure 1). In contrast to findings in ob/ob mice, plasma PAI-1 levels were associated negatively with total body weight (Figure 1) but positively with liver mass (r=0.51, P<0.01), and no significant correlation was found between PAI-1 mRNA content and the degree of liver steatosis. After restricting the analysis to each group of mice, an association between plasma PAI-1 and liver mRNA content remained significant in the group with alcohol-induced liver steatosis (r=0.55, P=0.03) as well as in group without liver steatosis (r=0.52, P=0.05).
As in ob/ob mice, we assessed TNF and TNFRs in the liver. We found a significant association between liver TNFRII and PAI-1 antigen, PAI-1 mRNA, and triglyceride content (r=0.62, P<0.01; r=0.51, P<0.01; and r=0.43, P=0.02, respectively).
Study in Morbidly Obese Humans
As expected, higher levels of plasma PAI-1, insulin resistance markers, and liver enzymes were found in obese than in lean subjects (Table 3). In liver biopsies of obese subjects, computerized estimation of the steatosis surface had a median value of 2.38% (25th and 75th percentiles, 0.9% and 9.6%, respectively). Liver steatosis surface was correlated positively with serum AST (r=0.48, P<0.01), ALT (r=0.51, P<0.01), and -GT (r=0.38, P<0.02).
|
Positive correlations between plasma PAI-1 antigen and activity and some parameters of insulin resistance were expected but were rather weak in this morbidly obese, insulin-resistant population (Table 4). Furthermore, we observed that plasma PAI-1 activity was more strongly associated with liver steatosis surface and with liver enzymes (mainly AST). A multiple linear regression analysis, with plasma PAI-1 activity as the dependent variable and insulin levels and liver steatosis surface as independent variables, showed significant and independent association between these three variables. Liver steatosis surface (ß=0.43, P=0.005) and insulin levels (ß=0.36, P=0.02) contributed to 26% of the variability of plasma PAI-1 activity.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
PAI-1 is involved in the atherothrombotic process. An elevated plasma PAI-1 level might be considered a risk factor for cardiovascular events, but its predictive value disappears after adjustment for insulin resistance parameters.4 In insulin resistance with android obesity, plasma PAI-1 levels are increased. Therefore, several recent studies that aimed to determine PAI-1 origin were focused on adipose tissue. Generally, adipose tissue was found to be a potential contributor to elevated plasma PAI-1 concentration; however, as a source of PAI-1, it cannot satisfactorily explain the increase in plasma PAI-1 in insulin resistance. In this study, we extended the knowledge on PAI-1 by showing that its plasma levels are closely related to the degree of liver steatosis, regardless of its etiology, suggesting that fat accumulation in the liver is more closely related to plasma PAI-1 levels than fat accumulation in adipose tissue.
It was previously shown that genetically obese ob/ob mice, which develop fatty liver early in life, have 
2-fold higher PAI-1 expression in the liver than do control lean mice.8 Our study in ob/ob mice showed that plasma PAI-1 concentration is associated with fat accumulation in both adipose tissue (reflected by body weight) and liver (reflected by the degree of liver steatosis). PAI-1 antigen content in the liver was significantly higher than in the collected adipose tissue territories. Interestingly, plasma PAI-1 was associated with PAI-1 expression in the liver but not in adipose tissue. From these results, we concluded that the pathologic process of liver steatosis reflected systemic PAI-1 levels more importantly than adipose tissue accumulation. Our results in lean CB57/BL6 mice with alcohol-induced liver steatosis were in accordance with this concept. After we induced liver steatosis, there was a 2- to 3-fold increase in plasma PAI-1 levels and in liver PAI-1 expression compared with those values in the control group. Plasma PAI-1 levels were associated with fat accumulation in the liver as well as with PAI-1 expression in the liver. Importantly, we found a significant, negative correlation between body weight and plasma PAI-1. This further suggests that PAI-1 production in adipose tissue is no longer important for systemic PAI-1 in the presence of liver steatosis. In contrast to the model of ob/ob mice, in the model of alcohol-induced liver steatosis, no correlation between liver PAI-1 mRNA and the degree of liver steatosis was observed. This suggests that regulation of PAI-1 expression does not depend only on the accumulation of fatty acids in hepatocytes. An effect of alcohol on PAI-1 synthesis also could not be completely ruled off. Ethanol has been shown to decrease PAI-1 transcription in cultured human endothelial cells,32 and a 251-bp fragment of the PAI-1 gene promoter was involved in this phenomenon.33 However, short-term alcohol intake increased plasma PAI-1 levels in vivo,34 and long-term alcohol consumption was accompanied by increased plasma PAI-1 levels,35–37 but in these studies, the degree of liver steatosis was not measured.
In humans, only a few studies have revealed the relations between circulating PAI-1 and liver dysfunction, as assessed by increased liver enzyme activity.18–21 In our population of morbidly obese subjects, plasma PAI-1 was associated more strongly with AST than with ALT or -GT levels, suggesting a common triggering factor for AST release from damaged hepatocytes and elevated plasma PAI-1. The present study showed for the first time the association between histologically assessed degree of liver steatosis and plasma PAI-1 levels. In our population of patients with morbid obesity, this association appeared to be stronger than that observed between insulin resistance markers and circulating PAI-1. From results of the multivariate regression analysis, we found that both liver steatosis and insulin may regulate plasma PAI-1 levels in morbid obesity. Overall, these results support the possibility that in insulin resistance, a fatty liver is an important source of plasma PAI-1. Highly accordant with this hypothesis also are recent findings in HIV patients with antiretroviral therapy-associated lipodystrophy. The amount of liver fat, detected by magnetic resonance imaging, is significantly correlated with plasma PAI-1 antigen, and changes in the amount of liver fat after rosiglitazone treatment were associated with changes in plasma PAI-1 antigen levels.14 Furthermore, our hypothesis is further favored by evidence of an association between circulating PAI-1 and PAI-1 expression in the liver, but not in adipose tissue, in the mouse model. Unfortunately, we were unable to confirm this finding in obese humans, because storage of the liver tissue was not proceeded for mRNA detection.
The molecular basis of the relation between PAI-1 and NASH remains unknown. It has been shown that TNF hepatic expression is increased in ob/ob mice38 and also in mice with alcohol-induced liver disease,39 and it was purposed that TNF contributes to the mitochondrial dysfunction that is implicated in the pathogenesis of NASH and alcoholic steatohepatitis.40 Furthermore, in ob/ob mice, inactivation of both TNFRs (TNFRI and TNFRII) or the administration of TNF-neutralizing antibodies significantly reduced plasma PAI-1 levels.31 In this study, we showed for the first time that PAI-1 antigen is associated with TNF and TNFRII antigens in steatotic liver. Thus, dysregulation of the TNF pathway in fatty liver accompanies increased liver PAI-1 expression. Strong correlations between liver TNFRII and PAI-1 antigen, found in both animal models of liver steatosis, suggest that in such conditions, TNF signaling of PAI-1 is mediated through TNFRII or that PAI-1 and TNFRII are simultaneously expressed. Additional experiments should be performed to delineate the role of TNFRs in PAI-1 regulation during NASH. Nevertheless, we speculate that TNF-induced PAI-1 synthesis in NASH is one of the mechanisms for increased plasma PAI-1 in obesity with insulin resistance.
There is another potential mechanism for increased plasma PAI-1 in obesity, which includes a direct effect of free fatty acids. Resistance to the antilipolytic action of insulin in peripheral tissues, particularly abdominal adipose tissue, results in an increased liver supply of free fatty acids and enhanced triglyceride deposition in the liver.17,41 Lipoproteins can induce PAI-1 production in endothelial cells and hepatocytes.42–44 Recently, it was shown that the PAI-1 promoter contains sequences able to bind free fatty acids or VLDL response elements.45,46 Thus, free fatty acids might induce PAI-1 gene expression in the liver directly.
In conclusion, this study shows a strong relation between plasma PAI-1 and the degree of liver steatosis, which is independent of body (and adipose tissue) mass. Our results suggest that a complex interaction between free fatty acid accumulation in hepatocytes and innate immunity may be responsible for increased circulating PAI-1 in obesity with insulin resistance.
|
Acknowledgments |
|---|
This work was supported by grants from Institut National de la Santé et de la Recherche Médicale (INSERM-Centre d’Investigation Clinique, Hôpital Ste. Marguerite), the MENESR (Contrat Quadriennal), and the Fondation de France (No. 2001005208). D. Bastelica is a recipient from the Fondation pour la Recherche Médicale (FRM). We thank M. Verdier, O. Geel-Georgelin, and J-C. Coudeyre for excellent technical assistance.
Received March 7, 2003; accepted April 17, 2003.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Eitzman DT, Westrick RJ, Xu Z, Tyson J, Ginsburg D. Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery. Blood. 2000; 96: 4212–4215.
2. Luttun A, Lupu F, Storkebaum E, Hoylaerts MF, Moons L, Crawley J, Bono F, Poole AR, Tipping P, Herbert JM, Collen D, Carmeliet P. Lack of plasminogen activator inhibitor-1 promotes growth and abnormal matrix remodeling of advanced atherosclerotic plaques in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2002; 22: 499–505.
3. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987; 2: 3–9.[CrossRef][Medline] [Order article via Infotrieve]
4. Juhan-Vague I, Pyke SD, Alessi MC, Jespersen J, Haverkate F, Thompson SG. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris: ECAT Study Group: European Concerted Action on Thrombosis and Disabilities. Circulation. 1996; 94: 2057–2063.
5. Juhan-Vague I, Alessi MC. Regulation of fibrinolysis in the development of atherothrombosis: role of adipose tissue. Thromb Haemost. 1999; 82: 832–836.[Medline] [Order article via Infotrieve]
6. Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T, Yamashita S, Miura M, Fukuda Y, Takemura K, Tokunaga K, Matsuzawa Y. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med. 1996; 2: 800–803.[CrossRef][Medline] [Order article via Infotrieve]
7. Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes. 1997; 46: 860–867.[Abstract]
8. Samad F, Loskutoff DJ. Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice. Mol Med. 1996; 2: 568–582.[Medline] [Order article via Infotrieve]
9. Eriksson P, Reynisdottir S, Lonnqvist F, Stemme V, Hamsten A, Arner P. Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals. Diabetologia. 1998; 41: 65–71.[CrossRef][Medline] [Order article via Infotrieve]
10. Alessi MC, Bastelica D, Morange P, Berthet B, Leduc I, Verdier M, Geel O, Juhan-Vague I. Plasminogen activator inhibitor 1, transforming growth factor-ß1, and BMI are closely associated in human adipose tissue during morbid obesity. Diabetes. 2000; 49: 1374–1380.[Abstract]
11. Mavri A, Alessi MC, Bastelica D, Geel-Georgelin O, Fina F, Sentocnik JT, Stegnar M, Juhan-Vague I. Subcutaneous abdominal, but not femoral fat expression of plasminogen activator inhibitor-1 (PAI-1) is related to plasma PAI-1 levels and insulin resistance and decreases after weight loss. Diabetologia. 2001; 44: 2025–2031.[CrossRef][Medline] [Order article via Infotrieve]
12. Bastelica D, Morange P, Berthet B, Borghi H, Lacroix O, Grino M, Juhan-Vague I, Alessi MC. Stromal cells are the main plasminogen activator inhibitor-1-producing cells in human fat: evidence of differences between visceral and subcutaneous deposits. Arterioscler Thromb Vasc Biol. 2002; 22: 173–178.
13. Hadigan C, Meigs JB, Rabe J, D’Agostino RB, Wilson PW, Lipinska I, Tofler GH, Grinspoon SS. Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab. 2001; 86: 939–943.
14. Yki-Jarvinen H, Sutinen J, Silveira A, Korsheninnikova E, Fisher R, Kannisto K, Ehrenborg E, Eriksson P, Hamsten A. Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy. Arterioscler Thromb Vasc Biol. 2003; 23: 688–694.
15. Reitman ML, Arioglu E, Gavrilova O, Taylor SI. Lipoatrophy revisited. Trends Endocrinol Metab. 2000; 11: 410–416.[CrossRef][Medline] [Order article via Infotrieve]
16. Arioglu E, Duncan-Morin J, Sebring N, Rother KI, Gottlieb N, Lieberman J, Herion D, Kleiner DE, Reynolds J, Premkumar A, Sumner AE, Hoofnagle J, Reitman ML, Taylor SI. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med. 2000; 133: 263–274.
17. Luyckx FH, Lefebvre PJ, Scheen AJ. Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss. Diabetes Metab. 2000; 26: 98–106.[Medline] [Order article via Infotrieve]
18. Asplund-Carlson A, Hamsten A, Wiman B, Carlson LA. Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo- and hypertriglyceridaemic men. Diabetologia. 1993; 36: 817–825.[CrossRef][Medline] [Order article via Infotrieve]
19. Bruckert E, Ankri A, Giral P, Turpin G. Relation between plasminogen activator inhibitor-1 and hepatic enzyme concentrations in hyperlipidemic patients. Thromb Haemost. 1994; 72: 434–437.[Medline] [Order article via Infotrieve]
20. Cigolini M, Targher G, Agostino G, Tonoli M, Muggeo M, De Sandre G. Liver steatosis and its relation to plasma haemostatic factors in apparently healthy men: role of the metabolic syndrome. Thromb Haemost. 1996; 76: 69–73.[Medline] [Order article via Infotrieve]
21. Bastard JP, Bruckert E, Porquet D, Jardel C, Ankri A, Delattre J, Hainque B. Evidence for a relationship between plasminogen activator inhibitor-1 and -glutamyl transferase. Thromb Res. 1996; 81: 271–275.[CrossRef][Medline]
[Order article via Infotrieve]
22. Henry M, Tregouet DA, Alessi MC, Aillaud MF, Visvikis S, Siest G, Tiret L, Juhan-Vague I. Metabolic determinants are much more important than genetic polymorphisms in determining PAI-1 activity and antigen plasma concentrations: a family study with part of the Stanislas Cohort. Arterioscler Thromb Vasc Biol. 1998; 18: 84–91.
23. Fan JG, Chen LH, Xu ZJ, Zeng MD. Overexpression of hepatic plasminogen activator inhibitor type 1 mRNA in rabbits with fatty liver. World J Gastroenterol. 2001; 7: 710–712.[Medline] [Order article via Infotrieve]
24. Alessi MC, Juhan-Vague I, Kooistra T, Declerck PJ, Collen D. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2. Thromb Haemost. 1988; 60: 491–494.[Medline] [Order article via Infotrieve]
25. Kooistra T, Bosma PJ, Tons HA, van den Berg AP, Meyer P, Princen HM. Plasminogen activator inhibitor 1: biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes. Thromb Haemost. 1989; 62: 723–728.[Medline] [Order article via Infotrieve]
26. Anfosso F, Chomiki N, Alessi MC, Vague P, Juhan-Vague I. Plasminogen activator inhibitor-1 synthesis in the human hepatoma cell line Hep G2: metformin inhibits the stimulating effect of insulin. J Clin Invest. 1993; 91: 2185–2193.[Medline] [Order article via Infotrieve]
27. Declerck PJ, Verstreken M, Collen D. Immunoassay of murine t-PA, u-PA and PAI-1 using monoclonal antibodies raised in gene-inactivated mice. Thromb Haemost. 1995; 74: 1305–1309.[Medline] [Order article via Infotrieve]
28. Morange PE, Lijnen HR, Alessi MC, Kopp F, Collen D, Juhan-Vague I. Influence of PAI-1 on adipose tissue growth and metabolic parameters in a murine model of diet-induced obesity. Arterioscler Thromb Vasc Biol. 2000; 20: 1150–1154.
29. Maniatis T, Fristsch EF, Sambrook J. Molecular Cloning : A laboratory Manual. 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1989.
30. Folch J. A simple method for the isolation and purification of total lipids from animal tissue. J Biol Chem. 1957; 226: 497–509.
31. Samad F, Uysal KT, Wiesbrock SM, Pandey M, Hotamisligil GS, Loskutoff DJ. Tumor necrosis factor- is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1. Proc Natl Acad Sci U S A. 1999; 96: 6902–6907.
32. Grenett HE, Aikens ML, Tabengwa EM, Davis GC, Booyse FM. Ethanol downregulates transcription of the PAI-1 gene in cultured human endothelial cells. Thromb Res. 2000; 97: 247–255.[CrossRef][Medline] [Order article via Infotrieve]
33. Grenett HE, Wolkowicz PE, Benza RL, Tresnak JK, Wheeler CG, Booyse FM. Identification of a 251-bp fragment of the PAI-1 gene promoter that mediates the ethanol-induced suppression of PAI-1 expression. Alcohol Clin Exp Res. 2001; 25: 629–636.[CrossRef][Medline] [Order article via Infotrieve]
34. van de Wiel A, van Golde PM, Kraaijenhagen RJ, von dem Borne PA, Bouma BN, Hart HC. Acute inhibitory effect of alcohol on fibrinolysis. Eur J Clin Invest. 2001; 31: 164–170.[CrossRef][Medline] [Order article via Infotrieve]
35. Mukamal KJ, Jadhav PP, D’Agostino RB, Massaro JM, Mittleman MA, Lipinska I, Sutherland PA, Matheney T, Levy D, Wilson PW, Ellison RC, Silbershatz H, Muller JE, Tofler GH. Alcohol consumption and hemostatic factors: analysis of the Framingham Offspring cohort. Circulation. 2001; 104: 1367–1373.
36. Dimmitt SB, Rakic V, Puddey IB, Baker R, Oostryck R, Adams MJ, Chesterman CN, Burke V, Beilin LJ. The effects of alcohol on coagulation and fibrinolytic factors: a controlled trial. Blood Coagulation Fibrinol. 1998; 9: 39–45.[Medline] [Order article via Infotrieve]
37. Marques-Vidal P, Cambou JP, Nicaud V, Luc G, Evans A, Arveiler D, Bingham A, Cambien F. Cardiovascular risk factors and alcohol consumption in France and Northern Ireland. Atherosclerosis. 1995; 115: 225–232.[CrossRef][Medline] [Order article via Infotrieve]
38. Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB, Desimone C, Song XY, Diehl AM. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology. 2003; 37: 343–350.[CrossRef][Medline] [Order article via Infotrieve]
39. Yin M, Wheeler MD, Kono H, Bradford BU, Gallucci RM, Luster MI, Thurman RG. Essential role of tumor necrosis factor- in alcohol-induced liver injury in mice. Gastroenterology. 1999; 117: 942–952.[CrossRef][Medline]
[Order article via Infotrieve]
40. Pessayre D, Mansouri A, Fromenty B. Nonalcoholic steatosis and steatohepatitis, V: mitochondrial dysfunction in steatohepatitis. Am J Physiol Gastrointest Liver Physiol. 2002; 282: G193–G199.
41. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, Forlani G, Melchionda N. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999; 107: 450–455.[CrossRef][Medline] [Order article via Infotrieve]
42. Allison BA, Nilsson L, Karpe F, Hamsten A, Eriksson P. Effects of native, triglyceride-enriched, and oxidatively modified LDL on plasminogen activator inhibitor-1 expression in human endothelial cells. Arterioscler Thromb Vasc Biol. 1999; 19: 1354–1360.
43. Banfi C, Mussoni L, Ris P, Cattaneo MG, Vicentini L, Battaini F, Galli C, Tremoli E. Very low density lipoprotein-mediated signal transduction and plasminogen activator inhibitor type 1 in cultured HepG2 cells. Circ Res. 1999; 85: 208–217.
44. Chautan M, Latron Y, Anfosso F, Alessi MC, Lafont H, Juhan-Vague I, Nalbone G. Phosphatidylinositol turnover during stimulation of plasminogen activator inhibitor-1 secretion induced by oxidized low density lipoproteins in human endothelial cells. J Lipid Res. 1993; 34: 101–110.[Abstract]
45. Chen Y, Billadello JJ, Schneider DJ. Identification and localization of a fatty acid response region in the human plasminogen activator inhibitor-1 gene. Arterioscler Thromb Vasc Biol. 2000; 20: 2696–2701.
46. Nilsson L, Gafvels M, Musakka L, Ensler K, Strickland DK, Angelin B, Hamsten A, Eriksson P. VLDL activation of plasminogen activator inhibitor-1 (PAI-1) expression: involvement of the VLDL receptor. J Lipid Res. 1999; 40: 913–919.
This article has been cited by other articles:
 |
|
 |
|
  R. Serrano, J. Barrenetxe, J. Orbe, J. A. Rodriguez, N. Gallardo, C. Martinez, A. Andres, and J. A. Paramo Tissue-specific PAI-1 gene expression and glycosylation pattern in insulin-resistant old rats Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2009; 297(5): R1563 - R1569. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Bortolotti, R. Kreis, C. Debard, B. Cariou, D. Faeh, M. Chetiveaux, M. Ith, P. Vermathen, N. Stefanoni, K.-A. Le, et al. High protein intake reduces intrahepatocellular lipid deposition in humans Am. J. Clinical Nutrition, October 1, 2009; 90(4): 1002 - 1010. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Oishi, D. Uchida, N. Ohkura, R. Doi, N. Ishida, K. Kadota, and S. Horie Ketogenic Diet Disrupts the Circadian Clock and Increases Hypofibrinolytic Risk by Inducing Expression of Plasminogen Activator Inhibitor-1 Arterioscler Thromb Vasc Biol, October 1, 2009; 29(10): 1571 - 1577. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Thuy, R. Ladurner, V. Volynets, S. Wagner, S. Strahl, A. Konigsrainer, K.-P. Maier, S. C. Bischoff, and I. Bergheim Nonalcoholic Fatty Liver Disease in Humans Is Associated with Increased Plasma Endotoxin and Plasminogen Activator Inhibitor 1 Concentrations and with Fructose Intake J. Nutr., August 1, 2008; 138(8): 1452 - 1455. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Targher, M. Chonchol, L. Bertolini, S. Rodella, L. Zenari, G. Lippi, M. Franchini, G. Zoppini, and M. Muggeo Increased Risk of CKD among Type 2 Diabetics with Nonalcoholic Fatty Liver Disease J. Am. Soc. Nephrol., August 1, 2008; 19(8): 1564 - 1570. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. de Larranaga, S. P. Wingeyer, M. Graffigna, S. Belli, K. Bendezu, S. Alvarez, O. Levalle, and H. Fainboim Plasma Plasminogen Activator Inhibitor-1 Levels and Nonalcoholic Fatty Liver in Individuals With Features of Metabolic Syndrome Clinical and Applied Thrombosis/Hemostasis, July 1, 2008; 14(3): 319 - 324. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Sozio and D. W. Crabb Alcohol and lipid metabolism Am J Physiol Endocrinol Metab, July 1, 2008; 295(1): E10 - E16. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Boullu-Ciocca, V. Achard, V. Tassistro, A. Dutour, and M. Grino Postnatal Programming of Glucocorticoid Metabolism in Rats Modulates High-Fat Diet-Induced Regulation of Visceral Adipose Tissue Glucocorticoid Exposure and Sensitivity and Adiponectin and Proinflammatory Adipokines Gene Expression in Adulthood Diabetes, March 1, 2008; 57(3): 669 - 677. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Westerbacka, M. Kolak, T. Kiviluoto, P. Arkkila, J. Siren, A. Hamsten, R. M. Fisher, and H. Yki-Jarvinen Genes Involved in Fatty Acid Partitioning and Binding, Lipolysis, Monocyte/Macrophage Recruitment, and Inflammation Are Overexpressed in the Human Fatty Liver of Insulin-Resistant Subjects Diabetes, November 1, 2007; 56(11): 2759 - 2765. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Targher, L. Bertolini, L. Scala, L. Zenari, G. Lippi, M. Franchini, and G. Arcaro Plasma PAI-1 Levels Are Increased in Patients With Nonalcoholic Steatohepatitis Diabetes Care, May 1, 2007; 30(5): e31 - e32. [Full Text] [PDF]
|
|
|
|
 |
|
 F. Dentali, E. Romualdi, and W. Ageno The metabolic syndrome and the risk of thrombosis Haematologica, March 1, 2007; 92(3): 297 - 299. [Full Text] [PDF]
|
|
|
|
|
|
S. Imagawa, S. Fujii, J. Dong, T. Furumoto, T. Kaneko, T. Zaman, Y. Satoh, H. Tsutsui, and B. E Sobel Hepatocyte Growth Factor Regulates E Box-Dependent Plasminogen Activator Inhibitor Type 1 Gene Expression in HepG2 Liver Cells Arterioscler Thromb Vasc Biol, October 1, 2006; 26(10): 2407 - 2413. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-C. Alessi and I. Juhan-Vague PAI-1 and the Metabolic Syndrome: Links, Causes, and Consequences Arterioscler Thromb Vasc Biol, October 1, 2006; 26(10): 2200 - 2207. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Klover, A. H. Clementi, and R. A. Mooney Interleukin-6 Depletion Selectively Improves Hepatic Insulin Action in Obesity Endocrinology, August 1, 2005; 146(8): 3417 - 3427. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||